Roche and gene therapy rival bluebird bio are settling a short-lived trademark infringement lawsuit around the latter company’s sickle cell disease awareness campaign.
Roche’s gene therapy unit, Spark Therapeutics, and bluebird have jointly moved to dismiss the lawsuit thanks to a settlement agreement, according to a filing posted in a Delaware federal court.
A bluebird spokesperson confirmed the settlement but said the terms are confidential. Spark didn’t immediately reply to a request for comment. As of Wednesday morning, the bluebird campaign at question, dubbed “Be the Spark,” remains live.
